Home › Thyroid Cancer › NCT02609685

Active Surveillance of Papillary Thyroid Microcarcinoma

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Pathologically confirmed Bethesda V or VI thyroid nodules with papillary thyroid carcinoma or high clinical suspicion, or pathologically confirmed Bethesda III or IV nodules with BRAF mutation.
* 2.0 cm or smaller nodules by ultrasonographic criteria
* Ability to understand and the willingness to sign a written informed consent and HIPAA Authorization form
* Must be able to read and write English fluently to participate in the questionnaire portion of the study

Exclusion Criteria:

* High-grade or poorly differentiated PTC variants
* Central or lateral neck lymphadenopathy suspicious for PTC
* Unfavorable nodule location (e.g. Near dorsal surface (by recurrent laryngeal nerve); Adjacent to trachea (risk of cartilage invasion)
* History of radiation to neck

About the study

The purpose of this study is to better understand the outcomes of active surveillance (observation) instead of immediate surgery, which is the current standard of care for papillary thyroid microcarcinoma (PTMC). Patients with a 1.5 cm or smaller thyroid nodule(s) with papillary thyroid carcinoma will be eligible for the study.

What is being tested

• Active Surveillance (other)

Sponsor: Cedars-Sinai Medical Center · Participants: 216 · Started: May 13, 2016

Contact the study team

• Allen Ho, MD · Phone: 310-423-1220

Official record on ClinicalTrials.gov — NCT02609685

Locations in the U.S.

Conditions

• Thyroid Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.